临床荟萃
臨床薈萃
림상회췌
CLINICAL FOCUS
2015年
1期
74-77
,共4页
王勇%丁勇%邢家骝%张友仁%管美超
王勇%丁勇%邢傢騮%張友仁%管美超
왕용%정용%형가류%장우인%관미초
甲状腺危象%碘同位素%骨密度%抗甲状腺药
甲狀腺危象%碘同位素%骨密度%抗甲狀腺藥
갑상선위상%전동위소%골밀도%항갑상선약
thyroid crisis%iodine isotopes%bone density%antithyroid agents
目的:探讨甲状腺功能亢进患者131碘(131 I)治疗前后骨密度的变化特点及131 I 治疗甲状腺功能亢进的价值。方法通过对我科甲状腺功能亢进患者按照治疗前后、性别及年龄(女性绝经后及男性>50岁设定为高龄组,女性未绝经及男性≤50岁设为青年组)等因素进行分组,通过对131 I 治疗前[经过抗甲状腺药物(antithyroid drugs, ATD)治疗后]的骨密度及131 I 治疗后18个月的骨密度测定值进行分析;另选取同期健康体检者140例作为对照组。结果本组甲状腺功能亢进患者131 I 治疗前(ATD 治疗后)的骨密度较健康对照组减低,但同组经131 I 治疗后各部位骨密度较治疗前明显好转(P <0.05)。131 I 治疗前及治疗后不同性别、不同年龄组骨密度均有差异,且治疗后女性骨密度的变化值与男性组比较差异有统计学意义,青年组骨密度的变化值与高龄组差异有统计学意义(P <0.05)。男女高龄组骨密度的变化值差异亦有统计学意义(P <0.05)。结论甲状腺功能亢进时对骨密度影响较大,与性别、年龄及 ATD 的使用关系密切。ATD 治疗甲状腺功能亢进对骨密度的改善不显著,131 I 治疗后骨密度显著改善,131 I治疗甲状腺功能亢进较 ATD 对骨密度的恢复更具优势。
目的:探討甲狀腺功能亢進患者131碘(131 I)治療前後骨密度的變化特點及131 I 治療甲狀腺功能亢進的價值。方法通過對我科甲狀腺功能亢進患者按照治療前後、性彆及年齡(女性絕經後及男性>50歲設定為高齡組,女性未絕經及男性≤50歲設為青年組)等因素進行分組,通過對131 I 治療前[經過抗甲狀腺藥物(antithyroid drugs, ATD)治療後]的骨密度及131 I 治療後18箇月的骨密度測定值進行分析;另選取同期健康體檢者140例作為對照組。結果本組甲狀腺功能亢進患者131 I 治療前(ATD 治療後)的骨密度較健康對照組減低,但同組經131 I 治療後各部位骨密度較治療前明顯好轉(P <0.05)。131 I 治療前及治療後不同性彆、不同年齡組骨密度均有差異,且治療後女性骨密度的變化值與男性組比較差異有統計學意義,青年組骨密度的變化值與高齡組差異有統計學意義(P <0.05)。男女高齡組骨密度的變化值差異亦有統計學意義(P <0.05)。結論甲狀腺功能亢進時對骨密度影響較大,與性彆、年齡及 ATD 的使用關繫密切。ATD 治療甲狀腺功能亢進對骨密度的改善不顯著,131 I 治療後骨密度顯著改善,131 I治療甲狀腺功能亢進較 ATD 對骨密度的恢複更具優勢。
목적:탐토갑상선공능항진환자131전(131 I)치료전후골밀도적변화특점급131 I 치료갑상선공능항진적개치。방법통과대아과갑상선공능항진환자안조치료전후、성별급년령(녀성절경후급남성>50세설정위고령조,녀성미절경급남성≤50세설위청년조)등인소진행분조,통과대131 I 치료전[경과항갑상선약물(antithyroid drugs, ATD)치료후]적골밀도급131 I 치료후18개월적골밀도측정치진행분석;령선취동기건강체검자140례작위대조조。결과본조갑상선공능항진환자131 I 치료전(ATD 치료후)적골밀도교건강대조조감저,단동조경131 I 치료후각부위골밀도교치료전명현호전(P <0.05)。131 I 치료전급치료후불동성별、불동년령조골밀도균유차이,차치료후녀성골밀도적변화치여남성조비교차이유통계학의의,청년조골밀도적변화치여고령조차이유통계학의의(P <0.05)。남녀고령조골밀도적변화치차이역유통계학의의(P <0.05)。결론갑상선공능항진시대골밀도영향교대,여성별、년령급 ATD 적사용관계밀절。ATD 치료갑상선공능항진대골밀도적개선불현저,131 I 치료후골밀도현저개선,131 I치료갑상선공능항진교 ATD 대골밀도적회복경구우세。
ABSTRACT:Objective To investigate the characteristics of bone mineral density in hyperthyroidism patients before and after 131 I treatment and its clinical value for the disease.Methods Hyperthyroidism patients were grouped by the following factors:before and after treatment,gender and age (postmenopausal women and men older than 50 years were grouped into elder group;premenopausal women and men younger than 50 years were grouped into youth group).Before 131 I treatment,patients were treated with antithyroid drug(ATD).Then,the bone mineral density was detected.At 18 months after 131 I treatment,bone mineral density was detected again.140 healthy individuals were enrolled as control group at the same time.Results The bone mineral density of hyperthyroidism patients before 131 I therapy but after ATD treatment was significantly reduced as compared with that of the healthy individuals.After 131 I treatment,bone mineral density of each part improved significantly (P <0.05).Before and after 131 I treatment,bone mineral density was remarkably different between gender or age groups.The change in females bone mineral density was markedly different from that in males after 131 I treatment (P < 0.05).The change in bone mineral density of youth group was also prominently different from that of the elder group (P <0.05).For the elder group,bone mineral density changes were also different between men and women (P <0.05).Conclusion Hyperthyroidism has a great effect on bone mineral density,which is closely corelated with gender,age and the use of ATD.ATD treatment for hyperthyroidism has little effect on bone mineral density,whereas 131 I therapy can significantly improve bone mineral density,indicating that 131 I treatment has better effect on the bone mineral density recovery of hyperthyroidism than ATD treatment.